Paper Details

  1. Home
  2. Paper Details

Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma.

Author: DewildeSarah, Fox-RushbyJulia, NiebauerKimberly, RevickiDennis A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Moderate to severe asthma significantly affects people's quality of life, and many patients experience fluctuating asthma control despite following treatment guidelines. Omalizumab, a new medication, has been shown to be safe and effective for treating asthma triggered by IgE antibodies.
Paper Details　
Original Abstract of the Article :
Moderate-to-severe allergic asthma has a substantial impact on patients' quality of life (QOL). Despite care consistent with treatment guidelines, many patients with moderate-to-severe asthma still experience variability in asthma control, signaling an unmet need within this population. Omalizumab h...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1081-1206(10)61242-2

データ提供：米国国立医学図書館（NLM）

Omalizumab: A Oasis in the Desert of Allergic Asthma

Asthma, a relentless desert wind that constricts the airways, can severely impact quality of life. This study focuses on moderate-to-severe allergic asthma, a challenging condition that often defies conventional treatments. The authors explore the potential of omalizumab, a targeted therapy that blocks IgE, a key player in the allergic response. The study reveals promising results, demonstrating the efficacy and safety of omalizumab in improving asthma control and enhancing quality of life for patients suffering from this debilitating condition.

Finding Relief in the Dust Storm

The study's positive findings offer a much-needed oasis in the desert of allergic asthma. Omalizumab provides a new avenue for improving asthma control and alleviating the symptoms that often disrupt daily life. This targeted therapy offers a promising approach to manage the condition, potentially empowering patients to reclaim their quality of life.

A New Path Through the Desert

For those facing the challenges of allergic asthma, this study offers a glimmer of hope. The potential of omalizumab to improve asthma control and quality of life provides a renewed sense of optimism. Open communication with healthcare professionals and a commitment to managing the condition are essential in navigating the desert of allergic asthma.

Dr.Camel's Conclusion

This study, like a refreshing breeze in the desert, offers a glimpse into the future of allergic asthma management. Omalizumab, a targeted therapy, shows promise in improving asthma control and quality of life for patients. This research offers a beacon of hope in the ongoing quest for effective treatments for this challenging condition.
Date :
  1. Date Completed 2006-03-22
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

16498854

DOI: Digital Object Identifier

10.1016/S1081-1206(10)61242-2

Related Literature

Article Analysis
・Effective treatment of asthma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.